QUOTE AND NEWS
DailyFinance  Jul 17  Comment 
CEL-SCI Corporation (NYSE MKT:CVM) today announced that Sri Lanka’s Ministry of Health has cleared the Company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational ...
StreetInsider.com  Jul 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/CEL-SCI+Corp.+%28CVM%29+Approved+to+Begin+Enrollment+iof+Multikine+PHase+III+in+Austria/9644010.html for the full story.
StreetInsider.com  Jul 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/CEL-SCI+Corp.+%28CVM%29+Updates+on+Strong+Enrollment+Stats+for+Multikine+Phase+3/9627566.html for the full story.
StreetInsider.com  Jun 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/CEL-SCI+Corp.+%28CVM%29+Reports+Stronger+Enrollments+in+Multikine+Phase+III/9547756.html for the full story.
StreetInsider.com  Jun 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/CEL-SCI+Corp.+%28CVM%29+Approved+to+Conduct+Multikine+Phase+III+in+U.K./9543049.html for the full story.
DailyFinance  Apr 17  Comment 
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has closed an underwritten public offering of units consisting of an aggregate of 7,128,229 shares of common stock and warrants to...
StreetInsider.com  Apr 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/CEL-SCI+Corp.+%28CVM%29+Prices+%2410M+Stock%2C+Warrants+Offering/9376747.html for the full story.
Yahoo  Apr 12  Comment 
Eike Batista, who was Brazil's richest man for most of the past decade, is under investigation for allegedly engaging in insider trading while he chaired his now-bankrupt oil-producing and shipbuilding firms, securities industry watchdog CVM said...
DailyFinance  Apr 8  Comment 
CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Henry Ford Health System in Detroit, Michigan is the latest U.S. clinical center to join the Company’s Phase III head and neck cancer clinical trial of its...
SeekingAlpha  Apr 2  Comment 
BySharon di Stefano: With remarkable swiftness, Cel-Sci Corporation (CVM) has been enrolling patients for its large Phase III clinical trial testing lead drug Multikine in cancer of the head and neck, and in the process defeating skeptics that...




 

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.

CEL-SCI's lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is an immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. Data from Phase I and Phase II clinical trials suggest that Multikine simulates the activities of a healthy person's immune system, enabling it to use the body's own anti-tumor immune response. Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki